ECSP982801A - COMPOSITION FOR TREATING RESPIRATORY AND SKIN DISEASES - Google Patents
COMPOSITION FOR TREATING RESPIRATORY AND SKIN DISEASESInfo
- Publication number
- ECSP982801A ECSP982801A ECSP982801A ECSP982801A EC SP982801 A ECSP982801 A EC SP982801A EC SP982801 A ECSP982801 A EC SP982801A EC SP982801 A ECSP982801 A EC SP982801A
- Authority
- EC
- Ecuador
- Prior art keywords
- phenyl
- montelukast
- inflammation
- propyl
- hydroxy
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 230000000241 respiratory effect Effects 0.000 title 1
- 208000017520 skin disease Diseases 0.000 title 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 abstract 3
- 206010061218 Inflammation Diseases 0.000 abstract 2
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 abstract 2
- 208000002193 Pain Diseases 0.000 abstract 2
- 208000003251 Pruritus Diseases 0.000 abstract 2
- 206010039085 Rhinitis allergic Diseases 0.000 abstract 2
- 201000010105 allergic rhinitis Diseases 0.000 abstract 2
- 208000006673 asthma Diseases 0.000 abstract 2
- 230000004054 inflammatory process Effects 0.000 abstract 2
- 229960005127 montelukast Drugs 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- SFOVDSLXFUGAIV-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]-n-piperidin-4-ylbenzimidazol-2-amine Chemical compound C1=CC(F)=CC=C1CN1C2=CC=CC=C2N=C1NC1CCNCC1 SFOVDSLXFUGAIV-UHFFFAOYSA-N 0.000 abstract 1
- BAWMMJAUVBLLEE-UHFFFAOYSA-N 2-[2-[4-[bis(4-fluorophenyl)methyl]piperazin-1-yl]ethoxy]acetic acid Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 BAWMMJAUVBLLEE-UHFFFAOYSA-N 0.000 abstract 1
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 abstract 1
- -1 6,7-difluoro 2-quinolinyl Chemical group 0.000 abstract 1
- FWEOQOXTVHGIFQ-UHFFFAOYSA-N 8-anilinonaphthalene-1-sulfonic acid Chemical compound C=12C(S(=O)(=O)O)=CC=CC2=CC=CC=1NC1=CC=CC=C1 FWEOQOXTVHGIFQ-UHFFFAOYSA-N 0.000 abstract 1
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 abstract 1
- 206010011224 Cough Diseases 0.000 abstract 1
- 208000000059 Dyspnea Diseases 0.000 abstract 1
- 206010013975 Dyspnoeas Diseases 0.000 abstract 1
- 206010019233 Headaches Diseases 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 206010028735 Nasal congestion Diseases 0.000 abstract 1
- 208000005141 Otitis Diseases 0.000 abstract 1
- 206010037884 Rash pruritic Diseases 0.000 abstract 1
- 208000036071 Rhinorrhea Diseases 0.000 abstract 1
- 206010039101 Rhinorrhoea Diseases 0.000 abstract 1
- 201000009961 allergic asthma Diseases 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- GXDALQBWZGODGZ-UHFFFAOYSA-N astemizole Chemical compound C1=CC(OC)=CC=C1CCN1CCC(NC=2N(C3=CC=CC=C3N=2)CC=2C=CC(F)=CC=2)CC1 GXDALQBWZGODGZ-UHFFFAOYSA-N 0.000 abstract 1
- 229960001803 cetirizine Drugs 0.000 abstract 1
- 208000019258 ear infection Diseases 0.000 abstract 1
- 210000005069 ears Anatomy 0.000 abstract 1
- 229960001971 ebastine Drugs 0.000 abstract 1
- MJJALKDDGIKVBE-UHFFFAOYSA-N ebastine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)CCCN1CCC(OC(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 MJJALKDDGIKVBE-UHFFFAOYSA-N 0.000 abstract 1
- 229950003420 efletirizine Drugs 0.000 abstract 1
- 229960003449 epinastine Drugs 0.000 abstract 1
- WHWZLSFABNNENI-UHFFFAOYSA-N epinastine Chemical compound C1C2=CC=CC=C2C2CN=C(N)N2C2=CC=CC=C21 WHWZLSFABNNENI-UHFFFAOYSA-N 0.000 abstract 1
- 229960003592 fexofenadine Drugs 0.000 abstract 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 abstract 1
- 231100000869 headache Toxicity 0.000 abstract 1
- 230000007803 itching Effects 0.000 abstract 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 210000004877 mucosa Anatomy 0.000 abstract 1
- 201000009240 nasopharyngitis Diseases 0.000 abstract 1
- 230000036407 pain Effects 0.000 abstract 1
- 210000003254 palate Anatomy 0.000 abstract 1
- 230000002085 persistent effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 229960004583 pranlukast Drugs 0.000 abstract 1
- UAJUXJSXCLUTNU-UHFFFAOYSA-N pranlukast Chemical compound C=1C=C(OCCCCC=2C=CC=CC=2)C=CC=1C(=O)NC(C=1)=CC=C(C(C=2)=O)C=1OC=2C=1N=NNN=1 UAJUXJSXCLUTNU-UHFFFAOYSA-N 0.000 abstract 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
- 208000013220 shortness of breath Diseases 0.000 abstract 1
- 201000009890 sinusitis Diseases 0.000 abstract 1
- 206010041232 sneezing Diseases 0.000 abstract 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 abstract 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Una composición farmacéutica útil para el tratamiento del estornudo, picazón y goteo de la nariz, congestión nasal, enrojecimiento de los ojos, lagrimeo, picazón en los oidos o paladar, brevedad de la respiración, inflamación de la mucosa bronquil, volumen expiatorio forzado en un segundo (FEV), reducido, tos, erupción picazón en la piel, dolores de cabeza y dolores persistentes y dolores asociados con la rinitis alérgica, rinitis alérgica permanente, resfrios comunes, otitis, sinusitis, alergia, asma, asma alérgico y/o inflamación, en un organismo de mamífero que necesita este tratamiento. La composición comprende: i) una cantidad efectiva de al menos un antagonista de leucotrieno seleccionado de g) montelukast h) ácido 1-(((R)(3-(2-(6,7-difluoro 2-quinolinil)etenl)fenil)-2-(2-hidroxi 2-propil)fenil) metilcilopropanoacético; i) ácido 1-(((1(R)-3(3-2-(2,3-diclorotiene(3,2)piridin-5-il)-(E)-etenil)fenil-2-(2-(1hidroxi-1-metil-fenil)propil)tio)metil)ciclopropanoacético;j) pranlukast; o k) zafirtukast, o l) ácido (2-((2--ter-butil -2tiazoli-)-5benzofuranil)oximetil)fenil) acético, o su sal farmacéuticamente aceptable, mezclado con ii) una cantidad efectiva de al menos una anthhistamina que es desacarboetoxiloratidina, cetirizina, fexofenadina, ebastina, astemizol, norastemizol, epinastina, efletirizina o su sal farmacéuticamente aceptable. g) montelukast.A pharmaceutical composition useful for the treatment of sneezing, itching and runny nose, nasal congestion, red eyes, tearing, itchy ears or palate, shortness of breath, inflammation of the bronchial mucosa, forced expiatory volume in a second (FEV), reduced, cough, itchy rash, persistent headaches and aches and pains associated with allergic rhinitis, permanent allergic rhinitis, common colds, otitis, sinusitis, allergy, asthma, allergic asthma and / or inflammation , in a mammalian organism that needs this treatment. The composition comprises: i) an effective amount of at least one leukotriene antagonist selected from g) montelukast h) 1 - (((R) (3- (2- (6,7-difluoro 2-quinolinyl) etenl) phenyl acid ) -2- (2-hydroxy 2-propyl) phenyl) methylcylpropanoacetic; i) 1 - (((1 (R) -3 (3-2- (2,3-dichlorotiene (3,2) pyridin-5- yl) - (E) -ethenyl) phenyl-2- (2- (1-hydroxy-1-methyl-phenyl) propyl) thio) methyl) cyclopropanoacetic; j) pranlukast; ok) zafirtukast, ol) (2 - ((2-tert-butyl -2thiazoli -) - 5benzofuranyl) oxymethyl) phenyl) acetic acid, or its pharmaceutically acceptable salt, mixed with ii) an effective amount of at least one anthhistamine that It is desacarboethoxyloratidine, cetirizine, fexofenadine, ebastine, astemizole, norastemizole, epinastine, efletirizine or its pharmaceutically acceptable salt. g) montelukast.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ECSP982801 ECSP982801A (en) | 1998-12-21 | 1998-12-21 | COMPOSITION FOR TREATING RESPIRATORY AND SKIN DISEASES |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ECSP982801 ECSP982801A (en) | 1998-12-21 | 1998-12-21 | COMPOSITION FOR TREATING RESPIRATORY AND SKIN DISEASES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP982801A true ECSP982801A (en) | 1999-05-17 |
Family
ID=42043718
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSP982801 ECSP982801A (en) | 1998-12-21 | 1998-12-21 | COMPOSITION FOR TREATING RESPIRATORY AND SKIN DISEASES |
Country Status (1)
| Country | Link |
|---|---|
| EC (1) | ECSP982801A (en) |
-
1998
- 1998-12-21 EC ECSP982801 patent/ECSP982801A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO4980868A1 (en) | COMPOSITION FOR TREATING RESPIRATORY AND SKIN DISEASES | |
| RU2607892C2 (en) | Composition based on xylitol, preventing separation of slime and related methods and compositions | |
| ES2773142T3 (en) | New treatment | |
| BR0307050A (en) | Compound, pharmaceutical composition, methods for treating prostaglandin d2 mediated diseases, for treating nasal congestion, for treating allergic asthma, and for treating allergic rhinitis, pharmaceutically acceptable salt, and use of a compound or salt | |
| EP1089715A4 (en) | AQUEOUS COMPOSITIONS CONTAINING THE CORTICOSTEROIDS FOR NASAL OR PULMONAL ADMINISTRATION | |
| Rajguru | Nasal polyposis: current trends | |
| MXPA03011947A (en) | Olopatadine formulations for topical administration. | |
| WO2004043470A1 (en) | The use of an anti-allergy agent and a steroid to treat allergic rhinitis | |
| WO2002085308A3 (en) | Antisense and anti-inflammatory based compositions to treat respiratory disorders | |
| AR048343A1 (en) | THERAPEUTIC AGENTS FOR THE TREATMENT OF MIGRANA | |
| CA2328073A1 (en) | Methods and compositions using cetirizine in combination with leukotriene inhibitors for treating conditions responsive to leukotriene inhibition | |
| Johnson | Pulmonary toxicity of benzalkonium chloride | |
| ES2848977T5 (en) | Methods of treating eye conditions | |
| BR9914419A (en) | Perception improvement therapy | |
| Huang et al. | Is a diluted seawater-based solution safe and effective on human nasal epithelium? | |
| JP2006506414A5 (en) | ||
| RU2007138270A (en) | The combination of anticholinergics and antagonists of leukotriene receptors for the treatment of respiratory diseases and a pharmaceutical composition based on it | |
| AR054411A1 (en) | PHARMACEUTICAL COMBINATION THAT INCLUDES AN OLEFINAL COMPOUND OF 8- AZONIABICICLO [3.2.1] OCTANO AND ONE OR MORE THAN AVAILABLE THERAPEUTIC INGREDIENTS, PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS AND USING THOSE COMPONENTS TO PREPARE IT | |
| US20080139545A1 (en) | Formulation to treat ear infection | |
| Li et al. | The protective effect of an eye wash solution on the ocular surface damage induced by airborne carbon black exposure | |
| RU2009144286A (en) | COMPOSITIONS WITH N-HALOGENICATED AMINO ACID AND ANTI-INFLAMMATORY COMPOUNDS | |
| JP2005533076A (en) | Nasal composition comprising mucopolysaccharide and propylene glycol | |
| Horak et al. | Decongestant activity of desloratadine in controlled-allergen-exposure trials | |
| Dundar et al. | A safety investigation into topical effects of naproxen sodium on nasal epithelial cells and potential toxicity in local application | |
| BR0110845A (en) | Aniline Disulfide Derivatives for the Treatment of Allergic Diseases |